RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil

AstraZeneca250 enrolled

Overview

The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous NSCLC with or without AGA and received at least 1 line of systemic treatment after failing PTC between January 2017 and December 2024.

The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with advanced/metastaic non-squamous NSCLC with or without AGA and who have failed platinum-based chemotherapy and immunotherapy (for patients without AGA) or platinum-based chemotherapy and at least 1 line of targeted therapy (for patients with AGA). The study will be conducted on one cohort of patients regardless their AGA status. The study index date will be defined as first dose of any agent after PTC, with specific treatments received for AGA and non-AGA patients in the preindex period. We will also conduct a subgroup analysis on NSCLC pre-defined subtypes (sample size permitting): EGFR mutant, ALK translocation, ROS1 translocation, MET1 mutant, HER-2 mutant, BRAF mutant, pan-wild-type PD-L1 \>50%.

Study Type

OBSERVATIONAL

Enrollment

250

Conditions

Non-squamous Non-Small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria * Confirmed diagnosis of non-squamous NSCLC, Stage IIIB/IIIC incurable or IV/M1. * Age ≥ 18 years at diagnosis of advanced/metastatic disease. AGA Cohort: Presence of actionable mutations and all of the following: * failure of platinum-based chemotherapy, * failure of ≥ 1 line of approved target therapy or no targeted therapy available at the clinic, * additional systemic treatment after platinum + target therapy combination. Non-AGA Cohort: Absence of actionable mutations and all of the following: * failure of platinum-based chemotherapy, * failure of immunotherapy concurrent or sequential to platinum, * additional systemic treatment after platinum + immunotherapy combination. Exclusion Criteria * Patients with evidence of other primary malignancies (except basal cell carcinoma and melanoma) within 1 year prior to the index date will be excluded from both study cohorts. * Patients who participated in a clinical investigational study for the treatment of any cancer, including NSCLC, or any early access program from 2018 onwards.

Locations (11)

Research Site

Belo Horizonte, Minas Gerais, Brazil

NOT_YET_RECRUITING

Research Site

Belo Horizonte, Minas Gerais, Brazil

NOT_YET_RECRUITING

Research Site